Japer Therapeutics Warrants
JSPRW
18 hedge funds and large institutions have $1.86M invested in Japer Therapeutics Warrants in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
+$535K |
| 2 |
SRCM
Sage Rock Capital Management
New York
|
+$403K |
| 3 |
TCM
Tenor Capital Management
New York
|
+$196K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$147K |
| 5 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$147K |
Top Sellers
JSPRW Hedge Fund Activity: Q1 2020 in Review
18 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q1 2020, worth a combined $1.86M.
Buyers outnumbered sellers: 18 funds opened new JSPRW positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Owl Creek Asset Management, opening a new position worth an estimated $535K.
- 18 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $1.86M of Japer Therapeutics Warrants stock for Q1 2020.
- 18 funds opened new Japer Therapeutics Warrants positions in Q1 2020 and 0 closed out, a net change of +18 holders.
- The largest Japer Therapeutics Warrants buyer in Q1 2020 was Owl Creek Asset Management, an estimated $535K added.
Based on aggregated 13F filings for Q1 2020.